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Purpose: Resistance to clopidogrel is an unfavourable prognostic factor in patients undergoing PCI for acute coronary syndromes. The aim of this 
analysis was to assess long-term prognosis of patients who are resistant to clopidogrel and are undergoing elective PCI for stable coronary artery 
disease (CAD).
Methods: For the purpose of this analysis, patients randomized in the PRAGUE 8 trial were included. These patients (n=92) underwent elective 
PCI for proven or suspected stable CAD, and their platelet reactivity measurement by VASP was performed before and 12 hours after the 600mg 
clopidogrel loading dose. VASP phosphorylation data were expressed as a platelet reactivity index (PRI). Patients were divided into 2 groups 
according to their PRI values.
Resistance to clopidogrel nonresponder) was defined as a patient with PRI more than 50% 12hours after clopidogrel loading dose.
Patients were followed for 24 months. The occurrence of death, myocardial infarction (MI), revascularization (PCI/CABG), and stroke was analyzed.
Results: Results are summarized in table 1. Nonresponders to clopidogrel had significantly higher occurrence of MI as compared to the responders 
(7/45 15.56% vs. 1/47 2.13%, p=0.029). Combined clinical endpoint (death/MI/stroke) was significantly higher in the nonresponders (11/45 
24.44% vs. 3/47 6.67%, p=0.02).
Conclusions: Resistance to clopidogrel assessed by VASP is a significant negative predictor of long-term prognosis in patients undergoing elective 
PCI for stable CAD.
Table 1, 2 years follow up
Nonresponders, n=45 Responders, n=47
p- value
n % n %
Death 2 4.44% 1 2.13% 0.613
MI 7 15.56% 1 2.13% 0.029
Stroke 2 4.44% 1 2.13% 0.613
Revascularisation 3 6.67% 2 4.26% 0.674
death/MI/Stroke 11 24.44% 3 6.67% 0.020
Death/MI/Stroke/
Revascularisation
11 24.44% 5 10.64% 0.102
